Literature DB >> 25014180

Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal microbiota transplantation in relapsing and refractory community- and hospital-acquired Clostridium difficile infection.

Muhammad Ali Khan, Aijaz Ahmed Sofi, Usman Ahmad, Osama Alaradi, Abdur Rahman Khan, Tariq Hammad, Jennifer Pratt, Thomas Sodeman, William Sodeman, Sehrish Kamal, Ali Nawras.   

Abstract

OBJECTIVE: To report the efficacy and safety of, and patient satisfaction with, colonoscopic fecal microbiota transplantation (FMT) for community- and hospital-acquired Clostridium difficile infection (CDI).
METHODS: A retrospective medical records review of patients who underwent FMT between July 1, 2012 and August 31, 2013 was conducted. A total of 22 FMTs were performed on 20 patients via colonoscopy. The patients were divided into 'community-acquired' and 'hospital-acquired' CDI. Telephone surveys were conducted to determine procedure outcome and patient satisfaction. Primary cure rate was defined as resolution of diarrhea without recurrence within three months of FMT, whereas secondary cure rate described patients who experienced resolution of diarrhea and return of normal bowel function after a second course of FMT.
RESULTS: Nine patients met the criteria for community-acquired CDI whereas 11 were categorized as hospital-acquired CDI. A female predominance in the community-acquired group (88.89% [eight of nine]) was found (P=0.048). The primary cure rate was 100% (nine of nine) and 81.8% (nine of 11 patients) in community- and hospital-acquired CDI groups, respectively (P=0.189). Two patients in the hospital-acquired group had to undergo a repeat FMT for persistent symptomatic infection; the secondary cure rate was 100%. During the six-month follow-up, all patients were extremely satisfied with the procedure and no complications or adverse events were reported.
CONCLUSION: FMT was a highly successful and very acceptable treatment modality for treating both community- and hospital-acquired CDI.

Entities:  

Mesh:

Year:  2014        PMID: 25014180      PMCID: PMC4210234          DOI: 10.1155/2014/695029

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  10 in total

1.  Editorial: not so nosocomial anymore: the growing threat of community-acquired Clostridium difficile.

Authors:  Daniel A Leffler; J Thomas Lamont
Journal:  Am J Gastroenterol       Date:  2012-01       Impact factor: 10.864

2.  Fidaxomicin versus vancomycin for Clostridium difficile infection.

Authors:  Thomas J Louie; Mark A Miller; Kathleen M Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Sherwood Gorbach; Pamela Sears; Youe-Kong Shue
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

Review 3.  Treatment of Clostridium difficile-associated disease.

Authors:  Daniel A Leffler; J Thomas Lamont
Journal:  Gastroenterology       Date:  2009-05-07       Impact factor: 22.682

4.  The epidemiology of community-acquired Clostridium difficile infection: a population-based study.

Authors:  Sahil Khanna; Darrell S Pardi; Scott L Aronson; Patricia P Kammer; Robert Orenstein; Jennifer L St Sauver; W Scott Harmsen; Alan R Zinsmeister
Journal:  Am J Gastroenterol       Date:  2011-11-22       Impact factor: 10.864

Review 5.  Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection-pooled data analysis and a systematic review.

Authors:  Aijaz Ahmed Sofi; Ann Lynn Silverman; Sadik Khuder; Kjetil Garborg; Julie M A Westerink; Ali Nawras
Journal:  Scand J Gastroenterol       Date:  2012-11-19       Impact factor: 2.423

6.  Recommendations for surveillance of Clostridium difficile-associated disease.

Authors:  L Clifford McDonald; Bruno Coignard; Erik Dubberke; Xiaoyan Song; Teresa Horan; Preeta K Kutty
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-25       Impact factor: 3.254

7.  Outcomes in community-acquired Clostridium difficile infection.

Authors:  S Khanna; D S Pardi; S L Aronson; P P Kammer; L M Baddour
Journal:  Aliment Pharmacol Ther       Date:  2012-01-10       Impact factor: 8.171

8.  Prevalence and diversity of Clostridium difficile strains in infants.

Authors:  Clotilde Rousseau; Ludovic Lemée; Alban Le Monnier; Isabelle Poilane; Jean-Louis Pons; Anne Collignon
Journal:  J Med Microbiol       Date:  2011-03-10       Impact factor: 2.472

9.  Duodenal infusion of donor feces for recurrent Clostridium difficile.

Authors:  Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

10.  A case-control study of community-associated Clostridium difficile infection.

Authors:  M H Wilcox; L Mooney; R Bendall; C D Settle; W N Fawley
Journal:  J Antimicrob Chemother       Date:  2008-04-22       Impact factor: 5.790

  10 in total
  9 in total

1.  Hospitalization Type and Subsequent Severe Sepsis.

Authors:  Hallie C Prescott; Robert P Dickson; Mary A M Rogers; Kenneth M Langa; Theodore J Iwashyna
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

Review 2.  Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea.

Authors:  Tae-Geun Gweon; Yoo Jin Lee; Kyeong Ok Kim; Sung Kyun Yim; Jae Seung Soh; Seung Young Kim; Jae Jun Park; Seung Yong Shin; Tae Hee Lee; Chang Hwan Choi; Young-Seok Cho; Dongeun Yong; Jin-Won Chung; Kwang Jae Lee; Oh Young Lee; Myung-Gyu Choi; Miyoung Choi
Journal:  J Neurogastroenterol Motil       Date:  2022-01-30       Impact factor: 4.924

Review 3.  Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-07-01

4.  GUT in FOCUS Symposium NOBEL FORUM, Karolinska Institutet, February 2nd 2015.

Authors: 
Journal:  Microb Ecol Health Dis       Date:  2015-05-29

5.  Feces transplantation for recurrent Clostridium difficile infection: US experience and recommendations.

Authors:  Johan S Bakken
Journal:  Microb Ecol Health Dis       Date:  2015-05-29

6.  Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.

Authors:  Emilie Baro; Tatiana Galperine; Fanette Denies; Damien Lannoy; Xavier Lenne; Pascal Odou; Benoit Guery; Benoit Dervaux
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

7.  Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis.

Authors:  Simon Mark Dahl Baunwall; Mads Ming Lee; Marcel Kjærsgaard Eriksen; Benjamin H Mullish; Julian R Marchesi; Jens Frederik Dahlerup; Christian Lodberg Hvas
Journal:  EClinicalMedicine       Date:  2020-11-23

8.  Adverse events of fecal microbiota transplantation: a meta-analysis of high-quality studies.

Authors:  Lamprinos Michailidis; Alden C Currier; Michelle Le; Deborah R Flomenhoft
Journal:  Ann Gastroenterol       Date:  2021-07-02

9.  Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and meta-analysis.

Authors:  Gianluca Ianiro; Marcello Maida; Johan Burisch; Claudia Simonelli; Georgina Hold; Marco Ventimiglia; Antonio Gasbarrini; Giovanni Cammarota
Journal:  United European Gastroenterol J       Date:  2018-06-03       Impact factor: 4.623

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.